Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Chronic Neuropathic Pain.

• Status: Completed
• Trial end date: 2005-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Evaluate long-term safety and efficacy of pregabalin in patients with chronic neuropathic pain.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Pregabalin

Criteria

Inclusion Criteria:

• Must have met the inclusion criteria for the preceding double-blind BID study in diabetic neuropathy or postherpetic neuralgia.

• Must have received study medication under double-blind conditions.

Exclusion Criteria:

• Patients cannot participate if they experienced a serious adverse event during the previous double-blind BID study which was determined to be related to the study medication.